Compare AGYS & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGYS | DYN |
|---|---|---|
| Founded | 1963 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | N/A | 2020 |
| Metric | AGYS | DYN |
|---|---|---|
| Price | $121.14 | $20.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $142.20 | $40.00 |
| AVG Volume (30 Days) | 139.7K | ★ 3.2M |
| Earning Date | 01-20-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $299,809,000.00 | N/A |
| Revenue This Year | $17.52 | N/A |
| Revenue Next Year | $16.28 | N/A |
| P/E Ratio | $141.13 | ★ N/A |
| Revenue Growth | ★ 17.77 | N/A |
| 52 Week Low | $63.71 | $6.36 |
| 52 Week High | $145.25 | $26.22 |
| Indicator | AGYS | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 50.94 |
| Support Level | $118.29 | $18.43 |
| Resistance Level | $124.92 | $21.00 |
| Average True Range (ATR) | 3.11 | 1.31 |
| MACD | -0.50 | 0.01 |
| Stochastic Oscillator | 27.88 | 31.91 |
Agilysys Inc provides hospitality software delivering cloud-native SaaS and on-premise solutions for hotels, resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It derives maximum revenue from the provision of software subscription and maintenance services, followed by the provision of professional services, and the sale of products (proprietary software licenses, third-party hardware, and operating systems). Agilysys operates across North America, Europe, the Middle East, Asia-Pacific, and India.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.